Management Team
Glenn J. Gormley, M.D., Ph.D.|President and Chief Executive Officer
Gordon C. Shore, Ph.D. |Chief Scientific Officer and Co-founder
Michael Dixon, C.A. | Chief Financial Officer
Jean Viallet, M.D. | Chief Medical Officer
Pierre Beauparlant, Ph.D. | Vice President, Research and Scientific Development
Mark S. Berger, M.D. | Vice President, Clinical Development
Jeffrey R. Hincks, Ph.D. | Vice President, Drug Development
Mark Mariani, M.Sc. | Senior Director, Regulatory Affairs and Compliance
Glenn J. Gormley, M.D., Ph.D. | President and Chief Executive Officer
Prior to joining Gemin X, Dr. Gormley was Global Head of Clinical Development and Medical Affairs at Novartis. Prior to Novartis, he was Chief Medical Officer at AstraZeneca and a member of the executive management team. While at AstraZeneca Dr. Gormley served as a member of the Board of Trustees at the University of Delaware. Before joining AstraZeneca, he was Vice President and Head of U.S. Clinical Development at Merck & Co.
Dr. Gormley received his M.D. and Ph.D. in Chemistry from the University of Chicago and received board certifications in Pediatrics from UCLA and in Endocrinology from New York University.
return to top
Gordon C. Shore, Ph.D. | Chief Scientific Officer and Co-founder
Dr. Shore has pursued his academic career in the Department of Biochemistry and the Cancer Center at McGill University in Montreal. He is the author of over 120 research publications and is internationally recognized for his work in apoptosis, with emphasis on the role of apoptosis in cancer. He is the recipient of a number of scientific awards.
Dr. Shore oversees all discovery and preclinical research at Gemin X.
return to top
Michael Dixon, C.A. | Chief Financial Officer
Mr. Dixon's entire professional career has been centered around growth-oriented businesses, initially as a consultant with Price Waterhouse, and then in various senior finance positions in the private sector. Prior to joining Gemin X, he was Vice President, Finance with an early stage biomedical company in Toronto where he successfully financed the company's research and development efforts over a two-year period. A chartered accountant, Mr. Dixon has a proven track record in fundraising, contract negotiation and strategic planning.
Mr. Dixon received his Bachelor of Commerce degree from the University of Toronto in 1983 and earned his Chartered Accountant (Ontario) designation with Price Waterhouse in 1986.
Mr. Dixon leads Gemin X's financing efforts, manages financial reporting and controls as well as contract negotiation, and oversees various administrative functions.
return to top
Jean Viallet, M.D. | Chief Medical Officer
Prior to joining Gemin X as Vice President for Clinical Development in 2002, Dr. Viallet held senior positions at GlaxoSmithKline. He was Group Director, Clinical Development and Medical Affairs at GSK and was responsible for the support of Navelbine, a leading cancer therapeutic presently available on the market. In addition, he led development efforts for GSK’s dual kinase inhibitor and played a central role in Corixa’s pursuit of regulatory approval for Bexxar, a radioimmunotherapy presently under review for the treatment of multiply relapsed low-grade non-Hodgkin’s lymphoma.
Dr. Viallet previously held the position of Senior Director of Clinical Oncology at Sanofi-Synthélabo where he managed several clinical development projects including oxaliplatin and rasburicase, both now on the market. Dr. Viallet also held faculty appointments at McGill University and the Université de Montréal, and clinical appointments at the Hôpital Notre-Dame and the Montreal General Hospital.
Dr. Viallet has published 50 research and review articles on the molecular biology of cancer and in clinical oncology. He holds degrees in Biology and in Medicine from the Université de Montréal and received his oncology training at the National Cancer Institute in Bethesda, MD. He is the recipient of several professional and academic awards.
Dr. Viallet leads all aspects of Gemin X's clinical and regulatory affairs.
return to top
Pierre Beauparlant, Ph.D. | Vice President, Research and Scientific Development
Dr. Beauparlant leads drug discovery research at Gemin X Pharmaceuticals and is responsible for building and managing the company's intellectual property portfolio. Prior to joining Gemin X in 2000, Dr. Beauparlant led product marketing efforts and contributed to the development of several therapies in the fields of immunology and neuroscience at Novartis Pharmaceuticals. Dr. Beauparlant holds a Ph.D. in microbiology and immunology from McGill University. He has published close to 50 research papers and abstracts in the fields of molecular oncology and virology.
return to top
Mark S. Berger, M.D. | Vice President, Clinical Development
Prior to joining Gemin X, Dr. Berger was Group Director, Clinical Oncology, Oncology Medicine Development Centre at GlaxoSmithKline for 4 years. He played a major role in the development of clinical strategy and trials for Tykerb (lapatinib), GSK’s dual kinase inhibitor, which led to Tykerb approval for metastatic breast cancer. He previously worked for 6 years at Wyeth where as Senior Director in Oncology Clinical Development he led the clinical team that developed and received approval for Mylotarg (gemtuzumab ozogamicin), the first antibody-targeted chemotherapy agent, based on Phase 2 trial results.
Dr. Berger’s training includes a biology degree from Wesleyan University and medical education at the University of Virginia School of Medicine. He received post-graduate training as a Resident in Internal Medicine and Chief Medical Resident at Thomas Jefferson University Hospital, and then as a Hematology-Oncology fellow at the Hospital of the University of Pennsylvania. He pursued molecular oncology work at the Imperial Cancer Research Fund laboratories in London and as an assistant professor at the University of Pennsylvania prior to joining the pharmaceutical industry.
Dr. Berger leads Gemin X’s clinical development efforts.
return to top
Jeffrey R. Hincks, Ph.D. | Vice President, Drug Development
Dr. Hincks most recently served as Vice President, Preclinical Development at ViroPharma Incorporated. During his seven years at ViroPharm, he built the drug development group that supported the company’s early and late stage development programs. He was a member of the senior management team, provided leadership in submitting a number of INDs, designed Phase 1 to 3 clinical studies, and participated in the submission of the Picovir™ NDA.
Dr. Hincks previously held senior positions in the Preclinical Development and Drug Safety Assessment Group at Sanofi Pharmaceuticals and at Sterling Winthrop, Inc. He provided preclinical development support to oncology programs and was the project team leader for an early stage development program in oncology. He participated in the inlicensing, drug development and European registration of Eloxatin™.
Dr. Hincks received his Ph.D. from Utah State University and conducted postdoctoral studies in the Cancer Pharmacology Lab at AMC Cancer Research Center, Denver, CO.
Dr. Hincks leads the drug development activities at Gemin X.
return to top
Mark Mariani, M.Sc. | Senior Director, Regulatory Affairs and Compliance
Mr. Mariani has over 18 years experience working in large pharmaceutical companies (Wyeth, Schering Plough, Sanofi-Synthelabo), with 16 years experience in Regulatory Affairs. Mr. Mariani has extensive FDA application experience spanning the preparation, submission, and FDA approval stages of the regulatory cycle. His experience includes 8 INDs, 8 NDAs and 1 BLA.
Most notably, he was involved with the submission, review and approval of Eloxatin ™ indicated for the treatment of colorectal cancer, which received one of the fastest FDA approvals for an oncologic agent (46 days).
Mr. Mariani is responsible for all of Gemin X’s regulatory submissions to the FDA.
return to top
